(MRK), Bristol-Myers Squibb Co. (BMY) and Roche Holding AG (ROG) have opened a new front against cancer with the next generation of experimental drugs that use the human immune system to seek and destroy tumor cells.

Bristol-Myers Squibb Company (NYSE: BMY) today announced that new data on its approved and investigational immuno-oncology compounds, Yervoy and the investigational PD-1 receptor blocking antibody nivolumab, will be featured in six oral ...

Bristol Myers Squibb Co. (NYSE:BMY) shares gained 2.20% to $41.85. The company on May 3 announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for SUSTIVA� (efavirenz), including ...

Bristol Myers Squibb Co.'s YTD performance was recorded as 38.69% while its market capitalization was $72.83 billion. The company has P/B ratio of 5.34 while P/E ratio was booked as 50.39.

A $100,000 grant from Bristol-Myers Squibb Company (NYSE: BMY) will support a Center for Green Schools Fellow in New Jersey who will work with leaders from the state's 586 public school districts to provide direction, training and resources toward ...

The expectations from some of those companies, like Boston Scientific Corporation (NYSE:BSX), Bristol Myers Squibb Co. (NYSE:BMY), Colgate-Palmolive Company (NYSE:CL), ConocoPhillips (NYSE:COP) and Colfax Corp (NYSE:CFX) are discussed ...

Below is a chart of Bristol-Myers Squibb Co. versus Union Pacific Corp plotting their respective size rank within the S&P 500 over time (BMY plotted in blue; UNP plotted in green): Loading+chart+�+2013+TickerTech.

Bristol-Myers Squibb Co. (BMY) sued Roche Holding AG (ROG)'s Genentech unit seeking a court order that it doesn't infringe patents used to make treatments for cancer and autoimmune diseases.

(RTTNews.com) - Biopharmaceutical company Bristol-Myers Squibb Co. ( BMY ) Thursday reported a plunge in profit for the first quarter, as sales dropped 27 percent after U.S.

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association.